FINV
FINAL DECISION TRANSACTION PROCESSED BY IB
07/05/2026
Voltar para busca
Dado oficial do USPTO
QIAGEN PARTNER
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Snapshot rápido
QIAGEN PARTNER
ST13
US500000079409549Classe
5, 10, 44
Pedido
79409549
Registro
7979833
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
25
Atualização mais recente
08/05/2026
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
5, 10, 44
Data de depósito
21/10/2024
Data de registro
14/10/2025
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
14/10/2025
Última transação
08/05/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Código do desenho
4
Tipo de titular
99
Localização do titular
DE
Examinador
CASTRO, GIANCARLO
Unidade examinadora
M10
Localização atual
FILE REPOSITORY (FRANCONIA)
Titulares e representantes
Titulares
Qiagen GmbH
Representantes
G MATHEW LOMBARD LOMBARD & GELIEBTER LLP
Classificação técnica
Classes Nice
Classe 5Classe 10Classe 44
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Diagnostic preparations for medical or veterinary purposes; diagnostic preparations for humans for medical purposes; preparations for medical and veterinary purposesin particular diagnosticsfor markingamplifyingquantification and/or for the analysis of biopolymersin particular nucleic acids; chemicalbiochemical and biotechnological preparations for medical and veterinary purposesin particular reagentsenzymes and buffer solutions for markingamplifyingquantification and/or for the analysis of biopolymersin particular nucleic acidsin particular reagentsenzymes and buffer solutions for nucleic acid amplification; kits containing preparations for medical and veterinary diagnostic purposesin particular for markingamplifyingquantification and/or for the analysis of biopolymersin particular nucleic acidsin particular reagentsenzymes and buffer solutions for nucleic acid amplification; chemical reagents for medical purposes; cartridges containing medical diagnostic reagents for use in Polymerase Chain Reaction (PCR) or digital Polymerase Chain Reaction (PCR) instruments; medical diagnostic assays for testing of body samplesincluding bodily fluids and tissue in the detectionmonitoringprediction of disease or other conditionsdisease stateshormone leveldrug leveldrug responseorgan function effectivenessclinical response; diagnostic test kits comprised of medical diagnostic reagents and assays for testing in the field of medical diagnostics.
Classe 10
Apparatus for medical and veterinary diagnostic analysis and determination of medical and veterinary conditionsnamely DNA and RNA testing apparatus; Medical and veterinary equipment for diagnostic purposes; clinical medical laboratory apparatus and analytical instrumentsnamely digital Polymerase Chain Reaction (d PCR) instruments for use in in-vitro and in-vivo diagnostics; medical devices for detection of infectious diseasedigital polymerase chain reaction (dPCR) platforms; medical devices for use in pre-natal screeningsdigital polymerase chain reaction (dPCR) platform; medical devicesdigital polymerase chain reaction (dPCR) instruments for use in detectingdiagnosing and treating cancer and infectious diseasedigital polymerase chain reaction (dPCR) platform; medical devicesdigital polymerase chain reaction (dPCR) instruments for use in pre-natal screeningsdigital polymerase chain reaction (PCR) platform; medical devicesinstruments for use in measuring and quantifying copy number of DNA for medical diagnostic purposesdigital polymerase chain reaction (dPCR) platform; microfluidic plates for use as medical apparatus.
Classe 44
Testing servicesquantifying DNA and RNA for medicaldiagnostic and treatment purposes; rental of digital Polymerase Chain Reaction (PCR) apparatus; RNA or DNA analysis for cancer diagnosis and prognosis; Medical servicesin particular medical analysis in connection with the treatment of individuals; providing information in the fields of medicineveterinary medicine and pharmaceuticals; health centersgenetic centers providing medical diagnosticpreventive and curative therapy services for genetic disorderscancer treatment centersrare disease treatment centerschildren's hospitals and women's hospital; medical clinics; gene therapy services in the field of oncologyinfertilityprenatal diagnosticscarrier testinggenetically inherited diseases; medical laboratory services for the analysis of samples taken from patients.
Publicações
Histórico de despachos e eventos da marca no USPTO.
25 publicações encontradas
OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
30/04/2026
FICS
FINAL DISPOSITION NOTICE SENT TO IB
23/04/2026
FIMP
FINAL DISPOSITION PROCESSED
23/04/2026
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
13/04/2026
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
13/04/2026
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
14/01/2026
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
14/10/2025
R.PR
REGISTERED-PRINCIPAL REGISTER
14/10/2025
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
26/08/2025
PUBO
PUBLISHED FOR OPPOSITION
26/08/2025
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
20/08/2025
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
23/07/2025
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
16/07/2025
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
16/07/2025
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
16/07/2025
RFNT
REFUSAL PROCESSED BY IB
29/03/2025
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
11/03/2025
RFRR
REFUSAL PROCESSED BY MPU
11/03/2025
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
23/01/2025
CNRT
NON-FINAL ACTION WRITTEN
22/01/2025
DOCK
ASSIGNED TO EXAMINER
13/01/2025
MAFR
APPLICATION FILING RECEIPT MAILED
17/11/2024
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
17/11/2024
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
14/11/2024
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace QIAGEN PARTNER ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.